Meeting
2024 ASCO Annual Meeting
In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL.
Presenter
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT03589326
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 6533)
DOI
10.1200/JCO.2024.42.16_suppl.6533
Abstract #
6533
Poster Bd #
92
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Annual Meeting
Updates on Abstract 398868: First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Speaker: Elias Jabbour, MD
Videos & Slides
ASCO Plenary Series
First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Speaker: Elias Jabbour, MD
Videos & Slides
2020 ASCO Virtual Scientific Program
Time to Reflect on What We Do Below the Peritoneal Reflection
Speaker: Christopher Leigh Hallemeier, MD
Videos & Slides
2024 ASCO Annual Meeting
A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis.
Speaker: Patrick Hagen, MD, MPH